Intensity Therapeutics is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. We leverage our DfuseRxSM technology platform to create new drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Our lead product candidate, INT230-6, is currently being evaluated in a Phase 1/2 clinical study in patients with various types of advanced solid tumors. INT230-6 has the potential to induce an adaptive immune response that not only attacks the injected tumor, but also non-injected tumors and unseen micro-metastases. Intensity is based in Westport, Connecticut. For more information, please visit www.intensitytherapeutics.com and follow us on Twitter @IntensityInc.
Looking for a particular Intensity Therapeutics, Inc. employee's phone or email?
Intensity Therapeutics, Inc. Questions
The Intensity Therapeutics, Inc. annual revenue was $16 million in 2026.
Lew Bender is the Founder, President and CEO of Intensity Therapeutics, Inc..
8 people are employed at Intensity Therapeutics, Inc..
Intensity Therapeutics, Inc. is based in Shelton, Connecticut.
The NAICS codes for Intensity Therapeutics, Inc. are [541714, 54171, 54, 541, 32, 325, 5417].
The SIC codes for Intensity Therapeutics, Inc. are [873, 87].
Top Intensity Therapeutics, Inc. Employees
-
25+
-
Joe Talamo
Chief Financial Officer at Intensity Therapeutics, Inc.
Stamford, CT, US25+ -
22
-
15+
-
Alexandra Bender
Metadata Analyst at Intensity Therapeutics, Inc.
Los Angeles, CA, US13
Related Companies
